基于异源mrna的COVID-19疫苗增强剂在印度尼西亚年轻人中的反应性——简短交流

Q4 Medicine
Suryadinata Neneng, Christopher Paulus Mario, Imanuelly Michelle, Wijaya Ratna Sari, Cucunawangsih Cucunawangsih, Lugito Nata Pratama Hardjo
{"title":"基于异源mrna的COVID-19疫苗增强剂在印度尼西亚年轻人中的反应性——简短交流","authors":"Suryadinata Neneng,&nbsp;Christopher Paulus Mario,&nbsp;Imanuelly Michelle,&nbsp;Wijaya Ratna Sari,&nbsp;Cucunawangsih Cucunawangsih,&nbsp;Lugito Nata Pratama Hardjo","doi":"10.21010/Ajidv17i2.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heterologous priming with the inactivated SARS-CoV-2 vaccine (CoronaVac) and boosting with mRNA-based COVID-19 vaccine (Moderna or Pfizer) is currently recommended in Indonesia. The reactogenicity data of these heterologous vaccine regimens are not entirely available, particularly in young adults. The present study, therefore, aimed to evaluate the solicited local and systemic reactions in the first seven days post-vaccination either with Moderna or Pfizer vaccine among previous recipients of two doses of CoronaVac.</p><p><strong>Materials and methods: </strong>An electronic-based cross-sectional study was conducted among medical students at the Pelita Harapan University, Banten, Indonesia, who received mRNA-based COVID-19 vaccine following two doses of CoronaVac. Samples were collected using a cluster sampling technique. Comparison between groups was performed by Fisher's exact test.</p><p><strong>Results: </strong>A total of 72 participants, 23 (32%) of which received the Moderna vaccine and 49 (68%) received the Pfizer vaccine, were included in this study. The median age of participants was 21 (IQR 19-22) years old. The most common local and systemic events for mRNA-based COVID-19 vaccines were injection site pain, fever, headache, fatigue, myalgia, and arthralgia. Solicited local and systemic reactions were reported more frequently in Moderna recipients than Pfizer recipients. Most local and systemic reactions were graded as mild to moderate and did not lead to hospitalization.</p><p><strong>Conclusions: </strong>The reactogenicity of the heterologous prime-boost with CoronaVac and mRNA-based COVID-19 vaccine booster among young adults is reassuring, and no unexpected concerns were identified.</p>","PeriodicalId":39108,"journal":{"name":"African Journal of Infectious Diseases","volume":"17 2","pages":"9-13"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158954/pdf/","citationCount":"0","resultStr":"{\"title\":\"REACTOGENICITY OF HETEROLOGOUS MRNA-BASED COVID-19 VACCINE BOOSTER IN YOUNG ADULTS IN INDONESIA- A SHORT COMMUNICATION.\",\"authors\":\"Suryadinata Neneng,&nbsp;Christopher Paulus Mario,&nbsp;Imanuelly Michelle,&nbsp;Wijaya Ratna Sari,&nbsp;Cucunawangsih Cucunawangsih,&nbsp;Lugito Nata Pratama Hardjo\",\"doi\":\"10.21010/Ajidv17i2.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Heterologous priming with the inactivated SARS-CoV-2 vaccine (CoronaVac) and boosting with mRNA-based COVID-19 vaccine (Moderna or Pfizer) is currently recommended in Indonesia. The reactogenicity data of these heterologous vaccine regimens are not entirely available, particularly in young adults. The present study, therefore, aimed to evaluate the solicited local and systemic reactions in the first seven days post-vaccination either with Moderna or Pfizer vaccine among previous recipients of two doses of CoronaVac.</p><p><strong>Materials and methods: </strong>An electronic-based cross-sectional study was conducted among medical students at the Pelita Harapan University, Banten, Indonesia, who received mRNA-based COVID-19 vaccine following two doses of CoronaVac. Samples were collected using a cluster sampling technique. Comparison between groups was performed by Fisher's exact test.</p><p><strong>Results: </strong>A total of 72 participants, 23 (32%) of which received the Moderna vaccine and 49 (68%) received the Pfizer vaccine, were included in this study. The median age of participants was 21 (IQR 19-22) years old. The most common local and systemic events for mRNA-based COVID-19 vaccines were injection site pain, fever, headache, fatigue, myalgia, and arthralgia. Solicited local and systemic reactions were reported more frequently in Moderna recipients than Pfizer recipients. Most local and systemic reactions were graded as mild to moderate and did not lead to hospitalization.</p><p><strong>Conclusions: </strong>The reactogenicity of the heterologous prime-boost with CoronaVac and mRNA-based COVID-19 vaccine booster among young adults is reassuring, and no unexpected concerns were identified.</p>\",\"PeriodicalId\":39108,\"journal\":{\"name\":\"African Journal of Infectious Diseases\",\"volume\":\"17 2\",\"pages\":\"9-13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158954/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"African Journal of Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21010/Ajidv17i2.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21010/Ajidv17i2.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景:目前印度尼西亚推荐用灭活的SARS-CoV-2疫苗(CoronaVac)异种引物和基于mrna的COVID-19疫苗(Moderna或辉瑞)增强。这些异源疫苗方案的反应原性数据并不完全可用,特别是在年轻人中。因此,本研究旨在评估先前接种两剂CoronaVac的患者在接种Moderna或辉瑞疫苗后最初7天的局部和全身反应。材料和方法:在印度尼西亚万丹的Pelita Harapan大学的医学生中进行了一项基于电子的横断面研究,这些学生在接受两剂CoronaVac后接受了基于mrna的COVID-19疫苗。采用整群抽样技术收集样本。组间比较采用Fisher精确检验。结果:本研究共纳入72例受试者,其中23例(32%)接种了Moderna疫苗,49例(68%)接种了辉瑞疫苗。参与者的中位年龄为21岁(IQR 19-22)。基于mrna的COVID-19疫苗最常见的局部和全身事件是注射部位疼痛、发烧、头痛、疲劳、肌痛和关节痛。在Moderna接受者中,征求性局部和全身反应的报告比辉瑞接受者更频繁。大多数局部和全身反应被分级为轻度至中度,没有导致住院。结论:冠状病毒抗体和基于mrna的COVID-19疫苗增强剂异种源性增强在年轻人中的反应性令人放心,没有发现意外的担忧。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

REACTOGENICITY OF HETEROLOGOUS MRNA-BASED COVID-19 VACCINE BOOSTER IN YOUNG ADULTS IN INDONESIA- A SHORT COMMUNICATION.

REACTOGENICITY OF HETEROLOGOUS MRNA-BASED COVID-19 VACCINE BOOSTER IN YOUNG ADULTS IN INDONESIA- A SHORT COMMUNICATION.

Background: Heterologous priming with the inactivated SARS-CoV-2 vaccine (CoronaVac) and boosting with mRNA-based COVID-19 vaccine (Moderna or Pfizer) is currently recommended in Indonesia. The reactogenicity data of these heterologous vaccine regimens are not entirely available, particularly in young adults. The present study, therefore, aimed to evaluate the solicited local and systemic reactions in the first seven days post-vaccination either with Moderna or Pfizer vaccine among previous recipients of two doses of CoronaVac.

Materials and methods: An electronic-based cross-sectional study was conducted among medical students at the Pelita Harapan University, Banten, Indonesia, who received mRNA-based COVID-19 vaccine following two doses of CoronaVac. Samples were collected using a cluster sampling technique. Comparison between groups was performed by Fisher's exact test.

Results: A total of 72 participants, 23 (32%) of which received the Moderna vaccine and 49 (68%) received the Pfizer vaccine, were included in this study. The median age of participants was 21 (IQR 19-22) years old. The most common local and systemic events for mRNA-based COVID-19 vaccines were injection site pain, fever, headache, fatigue, myalgia, and arthralgia. Solicited local and systemic reactions were reported more frequently in Moderna recipients than Pfizer recipients. Most local and systemic reactions were graded as mild to moderate and did not lead to hospitalization.

Conclusions: The reactogenicity of the heterologous prime-boost with CoronaVac and mRNA-based COVID-19 vaccine booster among young adults is reassuring, and no unexpected concerns were identified.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
African Journal of Infectious Diseases
African Journal of Infectious Diseases Medicine-Infectious Diseases
CiteScore
1.60
自引率
0.00%
发文量
32
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信